Keros Therapeutics
KROS
80 hedge funds and large institutions have $600M invested in Keros Therapeutics in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 16 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
4% less funds holding
Funds holding: 83 → 80 (-3)
10.76% less ownership
Funds ownership: 71.38% → 60.62% (-11%)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
32% less capital invested
Capital invested by funds: $887M → $600M (-$287M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.7M |
| 2 |
Alkeon Capital Management
New York
|
+$9.75M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.72M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$7.5M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$85.1M |
| 2 |
CA
CHI Advisors
New York
|
-$15.4M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$6.65M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.28M |
| 5 |
VA
VR Adviser
New York
|
-$5.42M |
KROS Hedge Fund Activity: Q2 2021 in Review
80 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2021, worth a combined $600M — down 32% from $887M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KROS and 13 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 38 added.
The largest buyer was Fidelity Investments, adding an estimated $30.7M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $85.1M sold.
- 80 institutional investors held Keros Therapeutics (KROS) as of Q2 2021, down from 83 in Q1 2021.
- Funds reported $600M of Keros Therapeutics stock for Q2 2021, down 32% quarter-over-quarter.
- 13 funds opened new Keros Therapeutics positions in Q2 2021 and 16 closed out, a net change of -3 holders.
- The largest Keros Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $30.7M added.
- The largest Keros Therapeutics seller in Q2 2021 was Foresite Capital Management IV, an estimated $85.1M sold.
Based on aggregated 13F filings for Q2 2021.